An Ottawa tech firm is putting its unique DNA testing capabilities towards detecting early indicators of Alzheimer’s disease.
Spartan Bioscience announced Wednesday a partnership with the Global Alzheimer’s Platform Foundation to help recruit for clinical trials targeting the chronic neurodegenerative disease.
Spartan, known for its distinctive DNA testing cube, has developed a genetic pre-screening test capable of detecting whether subjects carry a particular gene variation that puts them at higher risk of developing Alzheimer’s. According to a release, these individuals might be “ideal clinical trial candidates” for research on the disease.
(Sponsored)
Inspired by love and loss, donor Tom Moore triples Giving Tuesday donations
For Tom Moore, a retired tech executive and longtime Ottawa resident, giving back to The Ottawa Hospital isn’t just a gesture of generosity. It’s personal. Tom grew up on a
Giving Guide 2025: Ottawa Regional Cancer Foundation
As Ottawa’s only Community Cancer Hub, we are delivering Supportive Cancer Care through dynamic collaborations with over 70 diverse community partners.
Through the announced partnership, Spartan will also contribute $5 from each sale of its pre-screening test towards GAP’s transportation program, which providers Alzheimer’s clinical trial participants with rides to and from their appointments.
Spartan notes that its test is currently cleared for research uses only, not diagnosis.
